{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-21-000521","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.303510+00:00","generated_at":"2026-06-28T10:18:54.707277+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KORU Medical Q3 net loss $1.1M; revenue $6.0M, 9% sequential growth","bullets":["Net revenue $6.0M, 9% sequential growth; adjusted net revenue up 9% YoY excluding prior year inventory stocking.","Net loss $1.1M ($0.02 per share) vs net income $0.2M ($0.01) in Q3 2020.","Gross margin 57.9%, down from 64.8% due to manufacturing transition delays and scrap reserve.","Received FDA 510(k) clearance for Hizentra 20ml prefilled syringe with Freedom Edge system.","Three leadership hires and strategic plan update scheduled for December 2, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-21-000521","json":"https://secwatch.observer/filing/0001161697-21-000521.json","markdown":"https://secwatch.observer/filing/0001161697-21-000521.md","text":"https://secwatch.observer/filing/0001161697-21-000521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169721000521/0001161697-21-000521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169721000521/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:18:54.707277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}